Eutilex Obtains U.S. Patent for CD8+ T Cell Isolation
[Asia Economy Reporter Kum Boryeong] Utilex announced on the 3rd that it has obtained a U.S. patent related to the 'Method for Isolation and Proliferation of Autoantigen-Specific CD8+ T Cells.'
Hot Picks Today
!["Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③](https://cwcontent.asiae.co.kr/asiaresize/93/2026051422512663865_1778766774.jpg)
"Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Utilex stated, "This patent concerns a method for selecting epitopes recognized by CD8+ T cells from autoantigens present in the blood of individual cancer patients, isolating autoantigen-specific CD8+ T cells using peptides of the selected epitopes, and a method for mass proliferation of CD8+ T cells using this technique," adding, "It can be applied to the treatment and improvement of cancer diseases without side effects."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
